[go: up one dir, main page]

MX2015011371A - Anticuerpos monoclonales anti-+)--metanfetamina. - Google Patents

Anticuerpos monoclonales anti-+)--metanfetamina.

Info

Publication number
MX2015011371A
MX2015011371A MX2015011371A MX2015011371A MX2015011371A MX 2015011371 A MX2015011371 A MX 2015011371A MX 2015011371 A MX2015011371 A MX 2015011371A MX 2015011371 A MX2015011371 A MX 2015011371A MX 2015011371 A MX2015011371 A MX 2015011371A
Authority
MX
Mexico
Prior art keywords
methanphetamine
methamphetamine
anti body
subject
body antibodies
Prior art date
Application number
MX2015011371A
Other languages
English (en)
Other versions
MX378452B (es
Inventor
Samuel Michael Owens
Ralph Henry
Alicia Brown
Original Assignee
Univ Arkansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arkansas filed Critical Univ Arkansas
Publication of MX2015011371A publication Critical patent/MX2015011371A/es
Publication of MX378452B publication Critical patent/MX378452B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención abarca las composiciones y métodos para tratar con eficacia al menos un síntoma o señal de uso de la metanfetamina, o para disminuir la velocidad de entrada de (+) metanfetamina en el cerebro de un sujeto. El método comprende administrar una cantidad efectiva de un anticuerpo anti-(+) metanfetamina a un sujeto.
MX2015011371A 2013-03-13 2014-03-13 Anticuerpos monoclonales anti-+)--metanfetamina. MX378452B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/802,688 US9023353B2 (en) 2013-03-13 2013-03-13 Anti-(+)—methamphetamine monoclonal antibodies
PCT/US2014/025890 WO2014160133A2 (en) 2013-03-13 2014-03-13 Anti-(+) --methamphetamine monoclonal antibodies

Publications (2)

Publication Number Publication Date
MX2015011371A true MX2015011371A (es) 2015-12-16
MX378452B MX378452B (es) 2025-03-11

Family

ID=51527982

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011371A MX378452B (es) 2013-03-13 2014-03-13 Anticuerpos monoclonales anti-+)--metanfetamina.

Country Status (10)

Country Link
US (1) US9023353B2 (es)
EP (1) EP2970503B1 (es)
JP (2) JP2016514153A (es)
AU (1) AU2014244120B2 (es)
BR (1) BR112015020718A2 (es)
CA (1) CA2901514C (es)
ES (1) ES2923643T3 (es)
MX (1) MX378452B (es)
PL (1) PL2970503T3 (es)
WO (1) WO2014160133A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632929B2 (en) 2000-04-20 2009-12-15 The Board Of Trustees Of The University Of Arkansas Methamphetamine-like hapten compounds, linkers, carriers and compositions and uses thereof
CN117088982B (zh) * 2022-05-11 2024-06-21 东莞市朋志生物科技有限公司 抗甲基苯丙胺抗体、检测甲基苯丙胺的试剂和试剂盒
CN118440209B (zh) * 2022-06-21 2025-04-08 东莞市朋志生物科技有限公司 抗亚甲基双氧甲基苯丙胺抗体、检测亚甲基双氧甲基苯丙胺的试剂和试剂盒
CN119306842B (zh) * 2023-07-14 2025-08-12 东莞市朋志生物科技有限公司 抗甲基苯丙胺抗体、检测甲基苯丙胺的试剂和试剂盒

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041076A (en) 1967-01-10 1991-08-20 Kantor Frederick W Rotary inertial thermodynamic multi-stage mass-flow divider
US4041076A (en) 1974-10-23 1977-08-09 Hoffmann-La Roche Inc. Immunoassay for pharmacologically active phenethylamines
US4329281A (en) 1978-06-05 1982-05-11 Hoffmann-La Roche Inc. Hapten compositions
AU528246B2 (en) 1978-10-14 1983-04-21 Teikoku Hormone Mfg. Co., Ltd. Stable immunoassay reagent for hapten determination
DK159276C (da) 1980-03-31 1991-02-18 Takeda Chemical Industries Ltd Fremgangsmaade til isolering af specifikke antistoffer og enzym-immunbestemmelsesmetode med anvendelse af det isolerede antistof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5160701A (en) 1986-02-18 1992-11-03 Abbott Laboratories Solid-phase analytical device and method for using same
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPH0737986B2 (ja) 1988-03-29 1995-04-26 松下電器産業株式会社 免疫的検出方法
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5135863A (en) 1988-12-23 1992-08-04 Syntex (U.S.A.) Inc. Compositions and methods for determining the presence of amphetamines in a sample suspected of containing amphetamine and/or methamphetamine
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
US5141850A (en) 1990-02-07 1992-08-25 Hygeia Sciences, Inc. Porous strip form assay device method
US5238652A (en) 1990-06-20 1993-08-24 Drug Screening Systems, Inc. Analytical test devices for competition assay for drugs of non-protein antigens using immunochromatographic techniques
CH678394A5 (es) 1990-08-22 1991-09-13 Cerny Erich H
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5451504A (en) 1991-07-29 1995-09-19 Serex, Inc. Method and device for detecting the presence of analyte in a sample
CA2096495C (en) 1992-06-16 2002-07-09 Kathy Palmer Ordonez Dual analyte immunoassay
US5415994A (en) 1993-08-02 1995-05-16 Quidel Corporation Lateral flow medical diagnostic assay device with sample extraction means
US5492841A (en) 1994-02-18 1996-02-20 E. I. Du Pont De Nemours And Company Quaternary ammonium immunogenic conjugates and immunoassay reagents
US5620890A (en) 1995-03-14 1997-04-15 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to hygromycin B and the method of making the same
US5690942A (en) 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
ATE248192T1 (de) 1996-06-07 2003-09-15 Neorx Corp HUMANISIERTE ANTIKÖRPER DIE AN DAS GLEICHE ANTIGEN WIE ANTIKÖRPER NR-LU-13 BINDEN UND DEREN VERWENDUNG IN ßPRETARGETINGß VERFAHREN
IT1284076B1 (it) 1996-06-27 1998-05-08 Dox Al Italia Spa Frammenti f(ab')2 e relative immunoglobuline igg, attivi come anticorpi specifici verso farmaci e i loro metaboliti, e loro
DE19630102A1 (de) 1996-07-25 1998-01-29 Boehringer Mannheim Gmbh Neue aktivierte Amphetamine
US6087184A (en) 1997-11-10 2000-07-11 Beckman Coulter, Inc. Opposable-element chromatographic assay device for detection of analytes
US6306616B1 (en) 1998-03-27 2001-10-23 Microgenics Corporation Adsorption type confirmatory assays
CA2397839A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US6669937B2 (en) 2000-04-20 2003-12-30 The Board Of Trustees Of The University Of Arkansas Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs
WO2001081424A1 (en) 2000-04-20 2001-11-01 The Board Of Trustees Of The University Of Arkansas Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs
US7632929B2 (en) 2000-04-20 2009-12-15 The Board Of Trustees Of The University Of Arkansas Methamphetamine-like hapten compounds, linkers, carriers and compositions and uses thereof
US7202348B2 (en) 2000-04-20 2007-04-10 The University Of Arkansas For Medical Sciences Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs
US20030171435A1 (en) 2002-01-23 2003-09-11 Drug Abuse Sciences, Inc. New amphetamine derivatives, antibodies against them and pharmaceutical compositions containing them
EP1331219A1 (en) 2002-01-23 2003-07-30 Drug Abuse Sciences, Inc. New amphetamine derivatives, antibodies against them and pharmaceutical compositions containing them
ES2358737T3 (es) 2002-01-31 2011-05-13 Randox Laboratories Ltd. Inmunógenos, anticuerpos y conjugados para cetamina y sus metabolitos.
WO2004050032A2 (en) 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies against drugs of abuse
US20040242848A1 (en) 2003-04-21 2004-12-02 Owens S. Michael Mouse/human chimeric anti-phencyclidine antibody and uses thereof
US7674884B2 (en) * 2003-12-10 2010-03-09 Novimmune S.A. Neutralizing antibodies and methods of use thereof
US7037669B2 (en) 2004-03-22 2006-05-02 Dade Behring Inc. Assays for amphetamine and methamphetamine using stereospecific reagents
US7294649B2 (en) 2004-12-17 2007-11-13 Roche Diagnostics Operatins, Inc. Methamphetamine derivatives and conjugates for immunoassay
ES2415655T3 (es) 2006-06-15 2013-07-26 The Board Of Trustees Of The University Of Arkansas Anticuerpos monoclonales que reconocen selectivamente Metanfetamina y compuestos similares a Metanfetamina
US8853146B2 (en) * 2007-04-20 2014-10-07 The Board Of Trustees Of The University Of Arkansas Hapten compounds and compositions and uses thereof
US20100092470A1 (en) 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
CA2789071C (en) 2010-03-05 2018-03-27 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof

Also Published As

Publication number Publication date
WO2014160133A2 (en) 2014-10-02
EP2970503A2 (en) 2016-01-20
AU2014244120A1 (en) 2015-09-03
ES2923643T3 (es) 2022-09-29
BR112015020718A2 (pt) 2017-10-10
HK1215714A1 (en) 2016-09-09
MX378452B (es) 2025-03-11
US20140271686A1 (en) 2014-09-18
WO2014160133A3 (en) 2014-11-27
JP2016514153A (ja) 2016-05-19
CA2901514A1 (en) 2014-10-02
CA2901514C (en) 2021-02-16
PL2970503T3 (pl) 2022-08-29
EP2970503A4 (en) 2016-11-30
AU2014244120B2 (en) 2018-07-19
US9023353B2 (en) 2015-05-05
JP6560808B2 (ja) 2019-08-14
EP2970503B1 (en) 2022-06-22
JP2019069957A (ja) 2019-05-09

Similar Documents

Publication Publication Date Title
CL2018000429A1 (es) Moduladores de la expresión de kras
MX2016002826A (es) Anticuerpos anti-b7-h1 para tratar tumores.
WO2016062722A8 (en) Combination
EA201691214A1 (ru) Антитела к cd33 и иммуноконъюгаты
MX389684B (es) Anticuerpos anti tigit.
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
MX2020004503A (es) Anticuerpos cd3 humanizados o quimericos.
EA201690881A1 (ru) Соединения-ингибиторы аутотаксина
BR112018003526A2 (pt) métodos de tratamento de doenças inflamatórias
BR112017006940A2 (pt) triazolopirazinonas como inibidores de pde1
MX384909B (es) Un anticuerpo anti-tau para usarse al tratar una tauopatía.
MX2015012644A (es) Tratamiento de cataplejia.
EA201690406A1 (ru) Селективные ингибиторы grp94 и способы их применения
BR112015026660B8 (pt) Ligas metálicas aperfeiçoadas para dispositivos médicos
CL2017002719A1 (es) Imidazopirazinonas como inhibidores de pde1
UY35493A (es) Métodos para el tratamiento de la osteogénesis imperfecta
MX2016010085A (es) Metodos para tratar lesion del cerebro leve.
MX2015006337A (es) Metodos y composiciones para tratar enfermedades neurodegenerativas.
ECSP16061208A (es) Quinazolin-thf-aminas como inhibidores de pde1
EA201892552A1 (ru) Фармацевтические композиции, содержащие антиоксиданты, направленные на митохондрии
MX2015016628A (es) Metodo para tratar infeccion intracelular.
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
MX2015011371A (es) Anticuerpos monoclonales anti-+)--metanfetamina.
BR112016010635A2 (pt) composto para tratamento de hipoglicemia severa